Cancer Research and Treatment最新文献

筛选
英文 中文
Reactive Oxygen Species Modulator 1 Promotes Tumor Progression and Angiogenesis via the ROS-HIF-1α Axis in Lung Adenocarcinoma. 活性氧调节剂1通过ROS-HIF-1α轴促进肺腺癌的肿瘤进展和血管生成。
IF 4.2 2区 医学
Cancer Research and Treatment Pub Date : 2026-11-10 DOI: 10.4143/crt.2026.0578
Su Min Ji, Ye Won Jang, Hyeon Woo Ko, Ji Young Lee, Jae-Sun Choi, Joo-Won Jeong
{"title":"Reactive Oxygen Species Modulator 1 Promotes Tumor Progression and Angiogenesis via the ROS-HIF-1α Axis in Lung Adenocarcinoma.","authors":"Su Min Ji, Ye Won Jang, Hyeon Woo Ko, Ji Young Lee, Jae-Sun Choi, Joo-Won Jeong","doi":"10.4143/crt.2026.0578","DOIUrl":"https://doi.org/10.4143/crt.2026.0578","url":null,"abstract":"<p><strong>Purpose: </strong>Reactive oxygen species modulator 1 (Romo1) regulates intracellular reactive oxygen species (ROS) production. It has been reported to be upregulated in various cancers and contributes to tumor growth and metastasis. However, the role of Romo1 in tumor angiogenesis remains unclear.</p><p><strong>Materials and methods: </strong>Bioinformatic analysis assessed Romo1 expression and clinical significance in LUAD. Romo1 overexpression and knockdown were used to examine ROS production and expression of hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor A (VEGFA). YC-1, a HIF-1α inhibitor, was used to determine whether these effects are mediated by Romo1-induced HIF-1α upregulation. Pathway enrichment analysis and HIF-1α signature scoring were performed.</p><p><strong>Results: </strong>Romo1 is highly expressed in LUAD and is associated with aggressive pathological features and a poor prognosis. Romo1 induced ROS production and increased the expression of HIF-1α and VEGFA. Pathway enrichment analysis linked Romo1-associated oxidative stress to the HIF-1 signaling pathway and angiogenesis. Romo1 enhanced the angiogenic activity of endothelial cells and tumor cell proliferation. In a mouse xenograft tumor model, Romo1 promoted tumor growth and angiogenesis through HIF-1α upregulation. HIF-1α inhibition suppressed Romo1-induced tumor cell proliferation and the angiogenic activities. Analysis of the LUAD dataset revealed a positive association between ROMO1 mRNA expression and HIF-1α signaling pathway activation.</p><p><strong>Conclusion: </strong>These findings provide novel insights into the mechanisms by which Romo1 contributes to tumor progression and angiogenesis in LUAD.</p>","PeriodicalId":49094,"journal":{"name":"Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149412270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Nationwide Study of Interobserver Agreement and Accuracy in HER2 Immunohistochemistry and the Impact of Artificial Intelligence on HER2 Interpretation. 一项关于HER2免疫组织化学观察者间一致性和准确性的全国性研究以及人工智能对HER2解释的影响。
IF 4.2 2区 医学
Cancer Research and Treatment Pub Date : 2026-11-02 DOI: 10.4143/crt.2026.0805
Hyunwoo Lee, Gyu Young Kim, Yoon Ah Cho, Gyungyub Gong, Hee Jin Lee, Byung-Kwan Jeong, Ji-Seon Jeong, Young Kyung Bae, Min Chong Kim, So Yeon Park, Jiwon Koh, Jee Yeon Kim, Ho-Chang Lee, Hee Sung Kim, Wan Seop Kim, Young Hee Maeng, Sun Young Kwon, Chungyeul Kim, Sun-Young Jun, Hye Jeong Choi, Somang Lee, Nora Jee-Young Park, Ae Ri Ahn, Hyun Joo Choi, Jeong Yun Shim, Ji-Young Kim, Su Jung Kum, Hyang Im Lee, Song-Hee Han, Youjeong Seo, Yoon Jin Cha, Junjeong Choi, Yo Han Jeon, Ji Min Na, Miseon Lee, Hera Jung, Yeonjin Jeon, Jinye Yoo, Gui Young Kwon, Eun Yoon Cho, Ji Shin Lee
{"title":"A Nationwide Study of Interobserver Agreement and Accuracy in HER2 Immunohistochemistry and the Impact of Artificial Intelligence on HER2 Interpretation.","authors":"Hyunwoo Lee, Gyu Young Kim, Yoon Ah Cho, Gyungyub Gong, Hee Jin Lee, Byung-Kwan Jeong, Ji-Seon Jeong, Young Kyung Bae, Min Chong Kim, So Yeon Park, Jiwon Koh, Jee Yeon Kim, Ho-Chang Lee, Hee Sung Kim, Wan Seop Kim, Young Hee Maeng, Sun Young Kwon, Chungyeul Kim, Sun-Young Jun, Hye Jeong Choi, Somang Lee, Nora Jee-Young Park, Ae Ri Ahn, Hyun Joo Choi, Jeong Yun Shim, Ji-Young Kim, Su Jung Kum, Hyang Im Lee, Song-Hee Han, Youjeong Seo, Yoon Jin Cha, Junjeong Choi, Yo Han Jeon, Ji Min Na, Miseon Lee, Hera Jung, Yeonjin Jeon, Jinye Yoo, Gui Young Kwon, Eun Yoon Cho, Ji Shin Lee","doi":"10.4143/crt.2026.0805","DOIUrl":"https://doi.org/10.4143/crt.2026.0805","url":null,"abstract":"<p><strong>Purpose: </strong>Accurate assessment of low levels of human epidermal growth factor receptor 2 (HER2) expression has become increasingly important with the expansion of HER2-targeted therapies to patients with HER2-low and HER2-ultralow breast cancer (BC). Following the introduction of revised College of American Pathologists (CAP) guidelines incorporating the HER2-ultralow (0+) category, we conducted a nationwide multireader study to evaluate interobserver variation in HER2 interpretation and to investigate the impact of artificial intelligence (AI)-assisted image analysis.</p><p><strong>Materials and methods: </strong>A total of 168 BC cases stained using the VENTANA HER2 (4B5) assay were digitized as whole-slide images (WSIs). Thirty-four board-certified breast pathologists independently reviewed all cases without AI assistance and repeated the assessment after a four-week washout period using AI support. Interobserver agreement, classification performance, and reading time were compared between the two phases.</p><p><strong>Results: </strong>AI assistance significantly improved interobserver agreement (Krippendorff's alpha, 0.7415 to 0.8849; Fleiss' kappa, 0.4492 to 0.7524; p<0.001). The largest gains in diagnostic performance were observed in HER2-ultralow and HER2 IHC 1+ BCs, with sensitivities improving from 48.5% to 73.9% and from 64.9% to 87.7%, respectively (p<0.001). Although overall reading time was not reduced in the unadjusted analysis, AI assistance shortened interpretation time in HER2-ultralow BCs by 3.12 seconds (5.1% reduction).</p><p><strong>Conclusion: </strong>AI-assisted assessment improved the reproducibility and diagnostic performance of HER2 interpretation, with the greatest benefit observed in clinically relevant HER2 low-expression categories. The reduced interpretation time in HER2-ultralow BCs further suggests that AI can improve efficiency in diagnostically challenging cases encountered in routine practice.</p>","PeriodicalId":49094,"journal":{"name":"Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149326650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time-Updated TNM Stage and Risk of Clinician-Documented Suicidal Ideation After Cancer Diagnosis: A Hospital-Based Cohort Study. 时间更新的TNM阶段和癌症诊断后临床记录的自杀意念的风险:一项基于医院的队列研究。
IF 4.2 2区 医学
Cancer Research and Treatment Pub Date : 2026-11-02 DOI: 10.4143/crt.2026.0078
Doo Woong Lee, Jae Won Oh, Ji Hyun Lee, Alexander C Tsai, Nak-Hoon Son, Chun Il Park, San Lee, Minkyu Jung
{"title":"Time-Updated TNM Stage and Risk of Clinician-Documented Suicidal Ideation After Cancer Diagnosis: A Hospital-Based Cohort Study.","authors":"Doo Woong Lee, Jae Won Oh, Ji Hyun Lee, Alexander C Tsai, Nak-Hoon Son, Chun Il Park, San Lee, Minkyu Jung","doi":"10.4143/crt.2026.0078","DOIUrl":"https://doi.org/10.4143/crt.2026.0078","url":null,"abstract":"<p><strong>Purpose: </strong>Suicide risk is elevated among patients with cancer, but how clinician-documented suicidal ideation varies across time-updated TNM stages remains unclear. We examined this association after cancer diagnosis.</p><p><strong>Materials and methods: </strong>We conducted a retrospective cohort study of 134,369 patients using tumor registry and clinical records from Yonsei Cancer Center covering 2005-2021. We identified clinician-documented suicidal ideation using rule-based keyword screening and manual contextual review of electronic medical records. TNM stage was classified as CIS or stages I-IV and updated across eligible intervals. We estimated hazard ratios (HRs) using a marginal structural Cox model (MSM).</p><p><strong>Results: </strong>During follow-up, clinician-documented suicidal ideation was recorded in 6,718 patients (5.0%). Compared with TNM stage I, adjusted HRs were 0.81 (95% CI, 0.61-1.07) for CIS, 1.36 (1.25-1.49) for stage II, 1.20 (1.11-1.31) for stage III, and 1.54 (1.43-1.67) for stage IV. The stage III estimate was lower than the stage II estimate.</p><p><strong>Conclusion: </strong>Time-updated TNM stage was associated with clinician-documented suicidal ideation after cancer diagnosis, with the highest adjusted hazard observed for stage IV. These findings highlight the relevance of cancer-stage information to psychosocial assessment in cancer care.</p>","PeriodicalId":49094,"journal":{"name":"Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149326651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Familial Risk of Biliary Tract Cancers among Offspring and Its Interaction with Gallstones: A Population-Based Cohort Study. 子代胆道癌的家族性风险及其与胆结石的相互作用:一项基于人群的队列研究
IF 4.2 2区 医学
Cancer Research and Treatment Pub Date : 2026-10-20 DOI: 10.4143/crt.2025.0664
Hyun Jung Kim, Tae Uk Kang, Heather Swan, Seon Mee Park
{"title":"Familial Risk of Biliary Tract Cancers among Offspring and Its Interaction with Gallstones: A Population-Based Cohort Study.","authors":"Hyun Jung Kim, Tae Uk Kang, Heather Swan, Seon Mee Park","doi":"10.4143/crt.2025.0664","DOIUrl":"https://doi.org/10.4143/crt.2025.0664","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to estimate the familial risk of biliary tract cancer (BTC) encompassing bile duct cancer (BDC) and gallbladder cancer (GBC) in offspring and to evaluate the interaction between family history and gallstones.</p><p><strong>Materials and methods: </strong>Korean National Health Insurance claims and Health Screening databases (2002-2018) were linked to create a cohort of 6,217,057 offspring and 3,655,642 parent couples from 1.4 million families. Incidence rate ratios (IRRs) and hazard ratios (HRs) compared BTC risk in offspring with versus without an affected parent. Interaction between family history and gallstones was assessed with the relative excess risk due to interaction (RERI). Subgroup analyses were stratified by age, sex, and residence in Clonorchis sinensis-endemic areas.</p><p><strong>Results: </strong>Offspring with an affected parent had a 2.17-fold higher BTC risk than those without (0.35 vs. 0.08 cases per 10,000 person-years). Maternal history conferred greater risk than paternal history (HR 3.20 vs. 1.33). The IRR was higher in younger offspring. GBC or BDC risk in offspring was significantly associated with maternal, but not paternal, history of the other biliary cancer type, whereas no same-site associations were detected. Familial risk was lower in endemic than in non-endemic regions. Offspring with both gallstones and a family history showed markedly elevated risk (HR 17.36; 95% CI 9.80-30.81), although the interaction was not statistically significant (RERI 7.63; 95% CI -2.32-17.58).</p><p><strong>Conclusion: </strong>Offspring with gallstones and a family history of BTC have more than a ten-fold increase in BTC risk. Early and intensive surveillance should be considered for this high-risk population.</p>","PeriodicalId":49094,"journal":{"name":"Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149247121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epigenetic-Targeting Regimens vs. Conventional Chemotherapy in Relapsed/Refractory PTCL: A Meta-Analysis. 复发/难治性PTCL的表观遗传学靶向治疗方案与常规化疗:荟萃分析
IF 4.2 2区 医学
Cancer Research and Treatment Pub Date : 2026-10-12 DOI: 10.4143/crt.2026.0505
Jinchul Kim, Jinhyun Cho, Moon Hee Lee, Sang Eun Yoon, Seok Jin Kim, Won Seog Kim
{"title":"Epigenetic-Targeting Regimens vs. Conventional Chemotherapy in Relapsed/Refractory PTCL: A Meta-Analysis.","authors":"Jinchul Kim, Jinhyun Cho, Moon Hee Lee, Sang Eun Yoon, Seok Jin Kim, Won Seog Kim","doi":"10.4143/crt.2026.0505","DOIUrl":"https://doi.org/10.4143/crt.2026.0505","url":null,"abstract":"<p><strong>Purpose: </strong>Relapsed/refractory peripheral T-cell lymphoma (R/R PTCL) lacks a uniform salvage standard and outcomes with conventional chemotherapy (CC) remain suboptimal. This meta-analysis compared epigenetic-containing regimens (Epi-Rx) and CC in R/R PTCL.</p><p><strong>Materials and methods: </strong>We searched MEDLINE, Embase, and the Cochrane Library through May 2025 for prospective or retrospective studies evaluating Epi-Rx (≥1 HDAC, DNMT/hypomethylating, or EZH1/2 inhibitor, alone or in combination) or CC without epigenetic agents. Random-effects models pooled single-arm proportions, with prespecified subgroup analyses and meta-regression.</p><p><strong>Results: </strong>Thirty-eight studies (2,170 patients; 24 Epi-Rx cohorts and 16 CC cohorts) were included. Pooled overall response rate (ORR) was comparable between Epi-Rx and CC (46% [95% CI, 40%-52%] vs. 47% [95% CI, 41%-54%]; p=0.77), whereas 1-year progression-free survival (PFS) rate favored Epi-Rx (28% [95% CI, 24%-32%] vs 20% [95% CI, 16%-23%]; p<0.01). In meta-regression, Epi-Rx was independently associated with improved 1-year PFS (but not ORR) after adjustment for the proportion of T-follicular helper (TFH)-type PTCL, advanced-stage disease, and previous treatment lines. The PFS advantage persisted with epigenetic monotherapy versus CC (26% [95% CI, 21%-31%] vs. 20%; p=0.04) and was most pronounced in cohorts with a median of one prior line (35% [95% CI, 27%-43%] vs. 20% [95% CI, 16%-24%]; p<0.01). One-year overall survival rate favored Epi-Rx (57% [95% CI, 51%-62%] vs. 41% [95% CI, 32%-50%]; p<0.01).</p><p><strong>Conclusion: </strong>Compared with CC, Epi-Rx may be associated with improved survival outcomes in R/R PTCL. Prospective comparative studies are warranted to confirm this finding.</p>","PeriodicalId":49094,"journal":{"name":"Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149185467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strategy Integrating Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors for Oligometastatic Non-Small Cell Lung Cancer: A Narrative Review. 结合立体定向放射治疗与免疫检查点抑制剂治疗寡转移性非小细胞肺癌的策略:叙述性综述。
IF 4.2 2区 医学
Cancer Research and Treatment Pub Date : 2026-10-08 DOI: 10.4143/crt.2026.0730
Gyu Sang Yoo, Jae-Uk Jeong, Jong Hoon Lee, Yong Chan Ahn, Ah Ram Chang, Eui Kyu Chie, Chai Hong Rim, Ah Reum Lim
{"title":"Strategy Integrating Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors for Oligometastatic Non-Small Cell Lung Cancer: A Narrative Review.","authors":"Gyu Sang Yoo, Jae-Uk Jeong, Jong Hoon Lee, Yong Chan Ahn, Ah Ram Chang, Eui Kyu Chie, Chai Hong Rim, Ah Reum Lim","doi":"10.4143/crt.2026.0730","DOIUrl":"https://doi.org/10.4143/crt.2026.0730","url":null,"abstract":"<p><p>The therapeutic approach for oligometastatic non-small cell lung cancer (NSCLC) is rapidly shifting from palliative care to curative-intent strategies. This shift is largely driven by the integration of immune checkpoint inhibitors (ICIs) and stereotactic body radiation therapy (SBRT). SBRT functions biologically as an \"in situ vaccine,\" inducing immunogenic cell death and activating the cGAS-STING pathway to enhance systemic anti-tumor immunity, whereas ICIs may help sustain this radiation-primed immune response. Randomized phase II trials and pooled analyses have suggested the potential clinical benefit of adding radiation to ICIs, particularly in tumors with low or absent PD-L1 expression. However, the phase II/III NRG-LU002 trial found no improvement in progression-free or overall survival with the addition of local consolidative therapy to maintenance systemic therapy, indicating that the incremental benefit of local therapy may be limited in patients already deriving effective disease control from contemporary systemic regimens. Retrospective studies, including those utilizing recursive partitioning analysis and PD-L1-based stratification, have proposed a \"risk-based\" approach in which patients with an intermediate metastatic burden and low PD-L1 expression may derive greater benefit; these observations remain hypothesis-generating and require prospective validation. Looking ahead, the field is moving towards precision radio-immunotherapy, in which molecular biomarkers and rationally designed dose-fractionation and sequencing strategies are aimed at improving clinical outcomes while minimizing toxicity for patients with oligometastatic NSCLC.</p>","PeriodicalId":49094,"journal":{"name":"Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase IIa Trial of Locoregional High-Dose Autologous Natural Killer Cell Therapy Combined with Hepatic Arterial Infusion Chemotherapy for Locally Advanced Hepatocellular Carcinoma. 局部高剂量自体自然杀伤细胞联合肝动脉输注化疗治疗局部晚期肝癌的IIa期临床研究。
IF 4.2 2区 医学
Cancer Research and Treatment Pub Date : 2026-10-07 DOI: 10.4143/crt.2026.0477
Hyeon-Jong Kim, Yang Seok Koh, Byung Chan Lee, Yang-Hyun Baek, Jung Gil Park, Jeong Won Jang, Hyung-Seok Kim, Je-Jung Lee, Sung Bum Cho, Woo Kyun Bae
{"title":"Phase IIa Trial of Locoregional High-Dose Autologous Natural Killer Cell Therapy Combined with Hepatic Arterial Infusion Chemotherapy for Locally Advanced Hepatocellular Carcinoma.","authors":"Hyeon-Jong Kim, Yang Seok Koh, Byung Chan Lee, Yang-Hyun Baek, Jung Gil Park, Jeong Won Jang, Hyung-Seok Kim, Je-Jung Lee, Sung Bum Cho, Woo Kyun Bae","doi":"10.4143/crt.2026.0477","DOIUrl":"https://doi.org/10.4143/crt.2026.0477","url":null,"abstract":"<p><strong>Purpose: </strong>Hepatocellular carcinoma (HCC) refractory to locoregional therapies remains a major clinical challenge. This study evaluated the efficacy and safety of locoregional high-dose autologous natural killer (NK) cell therapy combined with hepatic arterial infusion chemotherapy (HAIC) in patients with locally advanced HCC.</p><p><strong>Materials and methods: </strong>This open-label, multicenter, phase IIa study enrolled patients with locally advanced HCC refractory to standard care. Patients achieving stable disease (SD) or better after two HAIC cycles (5-fluorouracil and cisplatin) underwent two additional HAIC cycles followed by hepatic arterial NK cell infusion for up to two cycles. The primary endpoint was independent review committee (IRC)-assessed objective response rate (ORR). Secondary endpoints included investigator-assessed ORR, disease control rate (DCR), duration of response (DOR), time to progression (TTP), overall survival (OS), safety, and immunologic response. Tumor response was assessed per modified RECIST for HCC.</p><p><strong>Results: </strong>Of 17 enrolled patients, 16 were evaluable. IRC-assessed ORR was 68.75% (exact 95% confidence interval, 41.34-88.98) [complete response (CR): 18.75%; partial response (PR): 50.00%], and investigator-assessed ORR was 62.50%. Both assessments yielded a DCR of 100%. Median DOR was 12.65 and 10.48 months by IRC and investigator assessment, respectively. Median investigator-assessed TTP was 16.82 months; IRC-assessed TTP was not reached. Median OS was 24.05 months. No severe NK cell-related toxicities were observed.</p><p><strong>Conclusion: </strong>Locoregional high-dose autologous NK cell therapy following HAIC showed promising antitumor activity and an acceptable profile in selected patients with locally advanced HCC. These findings warrant validation in randomized trials designed to isolate the incremental contribution of NK cell therapy.</p>","PeriodicalId":49094,"journal":{"name":"Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence and Risk Factors for Development of Portal Hypertension and Sinusoidal Liver Injury Associated with T-DM1 in HER2-Positive Breast Cancer. her2阳性乳腺癌中与T-DM1相关的门脉高压和肝窦性损伤的发生率和危险因素
IF 4.2 2区 医学
Cancer Research and Treatment Pub Date : 2026-10-06 DOI: 10.4143/crt.2025.1385
Hee Woo Park, Seo Yoon Jang, Ji Young Choi, Won Chang, Hee Young Na, Kyoung Ho Lee, Su Yeon Kim, Jeongmin Seo, Heejung Chae, Koung Jin Suh, Se Hyun Kim, Yu Jung Kim, Jongmin Jee, Jee Hyun Kim, Sook-Hyang Jeong
{"title":"Incidence and Risk Factors for Development of Portal Hypertension and Sinusoidal Liver Injury Associated with T-DM1 in HER2-Positive Breast Cancer.","authors":"Hee Woo Park, Seo Yoon Jang, Ji Young Choi, Won Chang, Hee Young Na, Kyoung Ho Lee, Su Yeon Kim, Jeongmin Seo, Heejung Chae, Koung Jin Suh, Se Hyun Kim, Yu Jung Kim, Jongmin Jee, Jee Hyun Kim, Sook-Hyang Jeong","doi":"10.4143/crt.2025.1385","DOIUrl":"https://doi.org/10.4143/crt.2025.1385","url":null,"abstract":"<p><strong>Purpose: </strong>While an association between trastuzumab emtansine (T-DM1) and development of portal hypertension has been suggested, clinical studies on the incidence and risk factors remain limited.</p><p><strong>Materials and methods: </strong>HER2-positive breast cancer patients treated with T-DM1 as adjuvant or palliative therapy were retrospectively enrolled. The composite endpoint of portal hypertension and sinusoidal liver injury was defined as development of splenomegaly and at least one among gastroesophageal varices, spontaneous portosystemic shunt, or portal hypertensive ascites; or biopsy-confirmed sinusoidal obstruction syndrome. Splenomegaly was defined as ≥50% increase in spleen volume, measured from CT images using a deep learning algorithm and reviewed by an independent radiologist. Univariable and multivariable analyses identified potential risk factors.</p><p><strong>Results: </strong>A total of 173 patients (median age: 53 (28-80)) were analyzed. Patients received a median of 14 (2-18) T-DM1 cycles in the adjuvant (n=62) and 11 (2-84) in the palliative setting (n=111). Portal hypertension and sinusoidal liver injury occurred in 31 (17.9%) (adjuvant; 11.3%, palliative; 21.6%), splenomegaly in 86 (49.7%) patients (adjuvant; 32.3%, palliative; 59.5%). Eight cases (4.6%) of liver-related T-DM1 discontinuation and 5 cases (2.9%) of significant liver-related complications were identified (4 variceal bleeding, one portosystemic encephalopathy). Age at T-DM1 treatment ≥60 years (OR 2.7, p=0.027), cumulative dose ≥55 mg/kg (OR 2.7, p=0.029), and baseline platelet count ≤150 × 109/L (OR 12.7, p=0.008) were identified as potential risk factors; however, the latter two associations should be interpreted with caution because the cumulative-dose association likely reflects prolonged T-DM1 exposure and the association observed for low baseline platelet count was derived from a very small subgroup of six patients.</p><p><strong>Conclusion: </strong>Portal hypertension and sinusoidal liver injury are clinically significant in patients receiving T-DM1, warranting careful monitoring, especially in those with older age, low baseline platelet count, and prolonged T-DM1 exposure.</p>","PeriodicalId":49094,"journal":{"name":"Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utilization, Reimbursement, and Barriers to Accessing Sequencing Tests for Cancer Care in the Asia-Pacific Region: KSMO Initiatives to Address Cancer Care Inequity. 亚太地区癌症治疗测序检测的使用、报销和障碍:解决癌症治疗不平等的KSMO倡议。
IF 4.2 2区 医学
Cancer Research and Treatment Pub Date : 2026-10-01 Epub Date: 2025-12-19 DOI: 10.4143/crt.2025.896
Omali Pitiyarachchi, Aaron C Tan, Tawasapon Thambamroong, Rogelio Velasco, Yuji Uehara, Daphne Lee, Hsiang-Fong Kao, Vivek Agarwala, Yueh Ni Lim, Dimas Priantono, Ardhi Rahman Ahani, Kyaw Zin Win, Young Saing Kim, Changhoon Yoo
{"title":"Utilization, Reimbursement, and Barriers to Accessing Sequencing Tests for Cancer Care in the Asia-Pacific Region: KSMO Initiatives to Address Cancer Care Inequity.","authors":"Omali Pitiyarachchi, Aaron C Tan, Tawasapon Thambamroong, Rogelio Velasco, Yuji Uehara, Daphne Lee, Hsiang-Fong Kao, Vivek Agarwala, Yueh Ni Lim, Dimas Priantono, Ardhi Rahman Ahani, Kyaw Zin Win, Young Saing Kim, Changhoon Yoo","doi":"10.4143/crt.2025.896","DOIUrl":"10.4143/crt.2025.896","url":null,"abstract":"<p><strong>Purpose: </strong>The Asia-Pacific region is marked by healthcare diversity and economic disparity.</p><p><strong>Materials and methods: </strong>To understand the utilization and reimbursement practices of next-generation sequencing (NGS) and other sequencing methods relevant to oncology clinical practice in the region, a semi-structured survey was undertaken of respondents from 11 countries represented by the Korean Society of Medical Oncology (KSMO) 2024 Young Oncologist Forum alumni.</p><p><strong>Results: </strong>While 79% of respondents reported access to NGS at their institution, full government reimbursement was uncommon and varied by test type and clinical setting. Japan and South Korea offered the most comprehensive public coverage, including for circulating tumor DNA-based liquid biopsy. Lower- and upper-middle-income countries, such as the Philippines, Indonesia, and India, reported no government reimbursement, thus relying on user-pay methods or private insurance payments. One marked barrier to NGS reimbursement was the prohibitive cost of tests (100%), followed by a limited budget to fund testing (78.6%), and then by policy or regulatory restrictions (50.0%). On a similar note, insurance coverage (92.9%) and patient income (85.7%) were key concerns regarding access and equity to tests. Test reimbursement (or lack thereof) and cost were cited almost universally as the most elevated concerns by the respondents.</p><p><strong>Conclusion: </strong>The findings demonstrated a wide disparity in access, funding and reimbursement of sequencing tests across the region. Addressing cost, improving reimbursement mechanisms, and building infrastructure capacity will be critical for the equitable integration of NGS into routine cancer care in the Asia-Pacific.</p>","PeriodicalId":49094,"journal":{"name":"Cancer Research and Treatment","volume":" ","pages":"1025-1036"},"PeriodicalIF":4.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13680088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Occupational Lead Exposure on Lung Cancer Risk in Korean Male Workers: A Retrospective Cohort Study. 职业性铅暴露对韩国男性工人肺癌风险的影响:一项回顾性队列研究。
IF 4.2 2区 医学
Cancer Research and Treatment Pub Date : 2026-10-01 Epub Date: 2025-10-02 DOI: 10.4143/crt.2025.282
Kyung-Eun Lee, Sanggil Lee, Jin-Ha Yoon, Shinhee Ye
{"title":"Impact of Occupational Lead Exposure on Lung Cancer Risk in Korean Male Workers: A Retrospective Cohort Study.","authors":"Kyung-Eun Lee, Sanggil Lee, Jin-Ha Yoon, Shinhee Ye","doi":"10.4143/crt.2025.282","DOIUrl":"10.4143/crt.2025.282","url":null,"abstract":"<p><strong>Purpose: </strong>In 2006, the International Agency for Research on Cancer reported that inorganic lead is carcinogenic in animals but with limited evidence in humans. In addition, some studies have reported that exposure to lead increases the risk of lung cancer, but this remains controversial. Therefore, we aimed to assess the risk of developing lung cancer according to blood lead (PbB) levels in workers with occupational lead exposure.</p><p><strong>Materials and methods: </strong>A retrospective cohort study of male workers with 2009 PbB concentrations was conducted using nationwide special health examination data from 2009 to 2021 and cancer registry data from 1999 to 2020 from the Republic of Korea. Standardized incidence ratios (SIRs) for lung cancer risk at each PbB level were calculated with a 5-year wash-out period, adjusting for age, smoking status, duration of exposure, and the number of co-exposures to lung carcinogens.</p><p><strong>Results: </strong>The study included 26,092 workers with an average follow-up period of 9.98 years. Compared with workers with PbB levels < 3.130 μg/dL, the adjusted SIRs for lung cancer risk were 2.95 (95% confidence interval [CI], 1.47 to 5.27) and 3.13 (95% CI, 1.82 to 5.00) for workers with PbB levels of 3.130-4.899 and ≥ 4.900 μg/dL, respectively, indicating a significant dose-response trend.</p><p><strong>Conclusion: </strong>This study demonstrates a significant association between lead exposure and an increased risk of lung cancer, highlighting the need for stronger occupational health policies and ongoing monitoring of workers exposed to lead. The observed dose-response relationship underscores the importance of reassessing current occupational safety standards and strengthening measures to reduce lead exposure in the workplace.</p>","PeriodicalId":49094,"journal":{"name":"Cancer Research and Treatment","volume":" ","pages":"1092-1100"},"PeriodicalIF":4.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13680083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145207997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书